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Aims Sepsis-associated cardiac dysfunction represents an intrinsic impairment of cardiomyocyte func-
tion due in part to a decrease in myoﬁlament Ca
2þ sensitivity associated with a sustained increase in
cardiac troponin I (cTnI) phosphorylation at Ser23/24. Dephosphorylation of cTnI is under regulatory
control. Thus, muscarinic and adenosine A1-receptor agonists antagonize b-adrenergic stimulation via
activation of protein phosphatase 2A (PP2A). The aim of this study was to determine whether modu-
lation of PP2A and thus cTnI phosphorylation could improve sepsis-induced contractile dysfunction.
Methods and results Cardiomyocytes were isolated from control or septic mice 16–18 h after an injec-
tion of vehicle or lipopolysaccharide (LPS; 9 mg/kg ip) respectively. Protein expression and phosphatase
activity were determined in homogenates of control and septic hearts. Our data showed that LPS signiﬁ-
cantly increased cTnI phosphorylation at Ser23/24 in cardiomyocytes and reduced contraction
amplitude without affecting Ca
2þ-transients. Treatment of cardiomyocytes with the A1 agonist cyclo-
pentyladenosine (CPA) or the protein kinase A inhibitor H89 signiﬁcantly attenuated the LPS-induced
contractile dysfunction without effect on Ca
2þ-transients. Co-treatment with CPA and H89 completely
reversed the contractile dysfunction. Increased cTnI phosphorylation in septic hearts was associated
with a signiﬁcant reduction in the protein expression of both the catalytic and regulatory subunits
(B56a) of PP2A and a decrease in PP2A activity. CPA treatment of septic hearts increased PP2A activity.
An increase in the protein expression of demethylated PP2A and a decrease in the PP2A-methyltransfer-
ase (PPMT; the methyltransferase that catalyses this reaction) were also observed.
Conclusion These data support the hypothesis that sustained cTnI phosphorylation underlies the con-
tractile dysfunction seen in sepsis.
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1. Introduction
Endotoxemia and sepsis involve a major inﬂammatory
response, frequently associated with hypotension, vascular
hyporeactivity, cardiac depression, and multiple organ
failure. Despite prompt treatment with antibiotics and sup-
portive care, the mortality of septic patients is still high,
with the number of deaths from sepsis equalling the
number of deaths from myocardial infarction in the USA.
1
Myocardial dysfunction is a common complication in patients
with severe sepsis and results in a signiﬁcantly increased
mortality.
2 Such dysfunction is characterized by depressed
ejection fraction and stroke work and increased end-
diastolic volumes. Since the reduction in contractility is
independent of alterations in cardiac load or heart rate, it
largely represents an intrinsic depression of contractile
function.
3
Previous data from our laboratory have demonstrated that
16–18 h after LPS injection, endotoxemic rat hearts show
increased cardiac troponin I (cTnI) phosphorylation at
Ser23/24, residues that mediate protein kinase A (PKA)-
dependent reduction of myoﬁlament calcium (Ca
2þ) sensi-
tivity.
4 No reduction in the calcium transient was observed,
suggesting that a reduction in myoﬁlament Ca
2þ sensitivity
largely underlies the contractile dysfunction. More recent
studies have conﬁrmed the functional importance of
increased cTnI phosphorylation in endotoxemia by demon-
strating that mice with cardiac-speciﬁc replacement of
cTnI with slow skeletal TnI (ssTnI), which lacks the PKA * Corresponding author. Tel: þ44 20 7848 5359; fax: þ44 20 7848 5193.
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protected against LPS-induced cardiac dysfunction.
5 More-
over, this protection was also observed in Triton-skinned car-
diomyocytes. No degradation of cTnI or TnT in LPS-treated
animals was observed nor were differences in the phos-
phorylation of other myoﬁlament proteins between the
groups detected.
5 Such sustained increase in cTnI phos-
phorylation could result from either sustained kinase acti-
vation or inhibition of dephosphorylation pathways.
Although the pathways regulating cTnI phosphorylation at
the PKA sites are relatively well understood,
6 the mechan-
ism(s) regulating the dephosphorylation pathways remain
unclear. A major dephosphorylating enzyme is protein
phosphatase 2A (PP2A), a multimeric serine/threonine
phosphatase which dephosphorylates both cTnI and phos-
pholamban.
7 PP2A predominately exists in vivo as a hetero-
dimer of the catalytic subunit C constitutively bound to the
scaffolding subunit A. These can then further complex with
one of several regulatory B subunits. The B subunits contain
all the targeting information that directs the heterotrimer
to distinct intracellular locations.
8,9 A number of agonists
and compounds have been reported to activate PP2A includ-
ing the adenosine A1-receptor agonist cyclopentyladenosine
(CPA),
7,10,11 b2-adrenoceptor agonists,
12 cAMP,
13 PAK 1,
14
and Ca
2þ.
15 CPA has been shown by a number of authors to
induce the translocation of the C subunit of PP2A from the
cytosol to the membrane
7,10 and decrease phosphorylation
of a number of protein targets including cTnI.
7 Thus, the
aim of this study was to investigate whether changes in
the regulation of PP2A underlie the sustained phosphoryl-
ation of cTnI in myocytes from endotoxemic hearts.
2. Methods
2.1 Animal models
All experiments were performed in accordance with UK Home Ofﬁce
regulations and the investigation conforms with the Guide for the
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23 revised 1996). C57/
BL6 mice were injected with 7–9 mg/kg ip Escherichia coli bacterial
lipopolysaccharide (LPS; serotype 0.11: B4, Sigma Aldrich, UK) or an
equivalent volume of saline and sacriﬁced 16–18 h later.
2.2 Isolated myocytes
Ventricular myocytes were isolated from C57Bl/6 mice following a
modiﬁed version of the AfCS procedure protocol (# PP00000125)
(http://www.afcs.org). The digestion protocol typically yielded
60–70% rod-shaped, viable, Ca
2þ tolerant myocytes from both
control and septic hearts. The cells were stored in the ﬁnal buffer
at room temperature and used within 5–6 h. Some cells were
loaded with the ﬂuorescent Ca
2þ indicator Indo-1 AM (2 mmol/L)
as described previously.
16
Single myocyte contractility and indo-1 AM ﬂuorescence were
studied on the stage of an inverted ﬂuorescence microscope
(Nikon Diaphot) coupled to a dual emission spectrophotometer
(Cairn Research, Faversham, Kent) as described previously.
5,17
2.3 Ventricular homogenate preparation
Control and septic hearts were retrogradely perfused with Krebs–
Henseleit buffer (KHB) (CaCl2 1.25 mmol/L, glucose 10 mmol/L,
and Na–pyruvate 5.0 mmol/L; bubbled with 95%O2:5%CO2 at 378C)
at a constant coronary perfusion pressure of 75 mmHg. Hearts
were paced at 588 bpm. In some hearts, once the hearts were
stable the perfusate was switched to KHB+CPA (1 mmol/L) for
10 min, following which ventricles were snap-frozen in liquid nitro-
gen. All subsequent procedures were carried out at 48C. Ventricles
were thawed in buffer containing 250 mmol/L sucrose, 2 mmol/L
EDTA, 2 mmol/L EGTA, 20 mmol/L HEPES, protease inhibitor
cocktail, 1 mM sodium ortho-vanadate, and 1 mM NaF, pH 7.4,
and homogenized (10% w/v) by a hand-held ground glass grinder
and then sonicated three times in 10 s bursts. Samples were centri-
fuged (100 000 g for 1 h) to separate cytosolic and particulate
fractions.
2.4 Gel electrophoresis and immunoblot analysis
Samples were re-suspended in Laemlli buffer with reducing agents
and the protein levels were determined by RC-DC Bio-Rad protein
assay with BSA as standard. For western analysis, 30 mg of soluble
extract protein was used per lane. Samples were subjected to elec-
trophoresis (10% gel) and transferred to nitrocellulose. After block-
ing (3%BSA/TBST 1 h, RT), the membranes were probed using a
range of primary antibodies against PP2A B56a subunit (BD Trans-
duction Laboratories), PP2A-C subunit, PP2A-A subunit, PP2A
demethylated, P-TnI Ser23/24, total cTnI (Cell Signalling Techno-
logies), anti-PP2A-methyltransferase/PPMT1, clone 4A4, anti-Rac-1
clone 23A8 (Upstate Cell Signalling Solutions), and HRP-conjugated
secondary antibodies. The bound antibodies were visualized by
chemiluminescence detection and protein levels were quantiﬁed
by scanning densitometry using TotalLab& software.
2.5 Real-time reverse transcriptase–polymerase
chain reaction
Total RNA was puriﬁed from heart homogenate using an SV RNA
extraction kit (Promega, UK) and reverse transcribed using MLV-RT
(Promega). Expression of the B56a subunit of PP2A was analysed
by real-time RT–PCR using ﬂuorescent SYBR Green technology on a
Prism 7000 HT system (Applied Biosystems, USA), and with b-actin
mRNA used for normalization. To obtain quantitative results, stan-
dard curves were constructed from cDNA standards for the B56a
gene. Results were then normalized by expression as a molar/
molar ratio to b-actin. The following primers were used (50–30):
b-actin forward CGTGAAAAGATGACCCAGATCA, reverse TGGTAC-
GACCAGAGGCATACAG; B56a forward TACAGTTGGTGTAT-
GAATTCTTCTTGAG, reverse GAGCTGTTGGACAAACTTCTGATC.
2.6 Protein phosphatase 2A activity assay
Protein phosphatase 2A activity was measured in whole heart hom-
ogenate with a Malachite Green Phosphatase assay kit (Millipore).
Samples were homogenized with a Dounce homogenizer in ice cold
buffer containing 250 mM sucrose, 20 mM HEPES, 10 mM KCl,
1.5 mM MgSO4, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.1 mg/mL
PMSF, 45 mg/mL aprotinin, and 1 mM sodium vanadate. Samples
were then sonicated three times in 10 s bursts. The baseline phos-
phatase activity was measured and subtracted from all samples.
Detergent was not included in the assay buffer as it was found
that detergent reduced PP2A activity by 40% (data not shown).
Samples were diluted to 25 mg of protein with phosphate-free
buffer containing 0.1 M NaOH, 60 mM b-mercaptoethanol, 1 mM
MgCl2, 1 mM EGTA, 0.1 mM MnCl2 1 mM DTT, 10% glycerol, and
0.1 mg/mL BSA, pH 7.4, and added to the wells of a 96-well
plate. After addition of 5 mL of the phosphopeptide, samples were
incubated for 30 min at room temperature. The reaction was termi-
nated by addition of Malachite green solution. The colour was
allowed to develop for 15 min at room temperature and the free
phosphate levels were determined by measuring absorbance at
612 nm. The proportion of signal that could be inhibited by
okadaic acid (10 nM) was considered as the PP2A activity, which
was expressed as a percentage of total phosphatase activity.
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All data are shown as mean+SEM of at least three different exper-
iments. Signiﬁcance was determined either with an unpaired
two-way Student’s t-test or with one-way ANOVA with Student–
Newman–Keul’s post hoc analysis (Prism 4.0, GraphPad, USA). P ,
0.05 was considered signiﬁcant.
3. Results
3.1 Depression of cardiac function in septic
myocytes is reversed by the combination of an
A1 agonist and a protein kinase A inhibitor
In line with our previous studies,
5 unloaded sarcomere short-
ening (SS) and the maximum shortening velocity (Vmax) were
signiﬁcantly reduced in septic myocytes (P , 0.05; Figures 1
and 2A and B)1 6 –18 h following LPS administration. This
reduction in contractility was not associated with any
changes in the Ca
2þ-transients (Figures 1B and 2E–G),
suggesting that a decrease in myoﬁlament Ca
2þ sensitivity
underlies the contractile dysfunction induced by LPS. Treat-
ment of control cells with CPA (1 mmol/L) or H89 (1 mmol/L)
(individually or in combination) had no effect on SS or Vmax
(Figure 2A and B). In contrast, in septic cells, SS was signiﬁ-
cantly improved with either CPA or H89 (from 3.9+0.3% to
5.4+0.3% and 5.2+0.2%, respectively; P , 0.05;
Figure 2A) although the reduction in Vmax was not signiﬁ-
cantly altered (Figure 2B). Furthermore, when septic cells
were treated with both CPA and H89 together there was a
further improvement in SS (over and above either treatment
alone) to 7.0+0.5% (P , 0.05 vs. control septic or septic þ
CPA or H89; Figure 2A, C, and D). Thus, the combination
restored contraction amplitude such that it was not signiﬁ-
cantly different from that of control myocytes. None of
these treatments affected the Ca
2þ transient (Figure 2E–
G). The combination of CPA and H89 signiﬁcantly improved
Vmax to control levels (from 22.2+0.1 to 24.3+
0.3 mm/s; P , 0.01; Figure 2B).
3.2 Cyclopentyladenosine reverses increased
cardiac troponin I phosphorylation associated
with sepsis
In line with previous studies,
4 the depression in contractile
function in septic myocytes was associated with a signiﬁcant
(2-fold) increase in cTnI phosphorylation at Ser23/24 (P ,
0.05; Figure 3A). The increase in phosphorylation in septic
myocytes was equivalent to that achieved in control myo-
cytes with isoprenaline treatment. However, in septic
myocytes, isoprenaline was unable to elicit any additional
phosphorylation at Ser23/24 suggesting that these sites
may be already maximally phosphorylated.
In line with the hypothesis that increased cTnI phosphoryl-
ation is a fundamental mechanism underlying the contrac-
tile defect in septic myocytes, CPA treatment completely
reversed the LPS-induced increase in Ser23/24 phosphoryl-
ation (Figure 3B).
3.3 Protein phosphatase 2A-C expression is
signiﬁcantly decreased in septic hearts
The increase in cTnI phosphorylation could result from either
a sustained kinase activation or decreased phosphatase (par-
ticularly PP2A) activity. Hence, we undertook a series of
experiments to investigate PP2A expression and activity in
control and septic hearts. Since the vast majority of the C
subunit resides in the cytosol and a relatively small percen-
tage of this is translocated to the particulate fraction upon
activation
7,10 for most experiments, western blot analysis
was performed on cytosolic and particulate fractions that
were probed for cTnI and Rac-1, respectively, to ascertain
fractionation (Figure 4A). In both cytosolic and particulate
fractions, PP2A-C expression was signiﬁcantly decreased in
septic ventricles (P , 0.05; Figure 4B). In contrast, PP1
expression was not signiﬁcantly altered in septic ventricles
in either the cytosolic or particulate fractions (Figure 4C).
3.4 Protein phosphatase 2A-B56a expression is
signiﬁcantly decreased in septic hearts
The B subunit of PP2A is thought to contain the targeting
information that directs the heterotrimer to speciﬁc cellular
compartments. Hence, loss of the B56a subunit may prevent
translocation of the catalytic unit to the required location.
Western blot analysis demonstrated a dramatic reduction
in the expression of the B56a subunit by 69+5% in septic
myocytes in the particulate fraction (Figure 5A). A trend
to a reduction in the cytosolic fraction was also observed,
although this did not reach statistical signiﬁcance
(Figure 5A). To determine whether this reduction in
protein levels was a result of a reduction at the mRNA
level, we analysed mRNA expression in whole heart hom-
ogenate. As shown in Figure 5B, mRNA levels of B56a
subunit showed a .50% reduction in septic hearts (LPS
0.046+0.008 vs. control 0.096+0.01 molar/molar ratio
to b-actin). No change in protein expression of PP2A-A
subunit was observed (Figure 5C).
Figure 1 (A) Representative trace of sarcomere shortening from representative myocytes from saline (black line)- or lipopolysaccharide (LPS; grey line)-treated
hearts. (B) Associated intracellular Ca
2þ-transients (Indo-1 410/480 ratio) of myocytes from saline (black trace)- or LPS (grey trace)-treated hearts.
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septic hearts
Post-translational methylation at Leu309 of the C subunit is
thought to be an important mechanism for regulating the
activity of PP2A. Methylation is thought to activate the
enzyme and allow binding of the B subunit. We used an anti-
body speciﬁc for the demethylated (i.e. inactive) form of
PP2A-C since there is no antibody available which recognizes
the methylated form. Figure 6A demonstrates that there
was a signiﬁcant increase in the level of the demethylated
form of PP2A-C in the particulate fraction of septic hearts.
No changes were observed with CPA treatment, suggesting
that CPA would not increase PP2A activity by increasing
the methylation status of the catalytic subunit in septic
hearts. No changes were observed in the cytosolic fractions
(data not shown). Furthermore, the expression of the
speciﬁc methyltransferase (PPMT) required to methylate
PP2A-C
18 was also shown to be signiﬁcantly decreased in
septic hearts (by 60% and 50%, respectively; Figure 6B).
Figure 2 (A) Averaged contraction data from saline- or lipopolysaccharide-treated mouse myocytes in the presence of cyclopentyladenosine (CPA) (1 mmol/L),
H89 (1 mmol/L), or co-treatment with both CPA and H89 (n ¼ 80–100 cells from three hearts; *P , 0.01) and (B) maximum shortening velocity (Vmax, mm/s). (C
and D) Representative traces for single cells showing the effect of co-treatment with both CPA and H89 for 10 min on a control (C) and septic cell (D). (E) Ampli-
tude of Ca
2þ-transients (Indo-1 410/480 ratio) and RT50 (ms) of Ca
2þ-transients in the presence of (F) CPA or (G) H89. Bars represent mean+SE of the mean.
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respectively. (B) Representative blot and quantiﬁcation of the amount of total protein phosphatase 2A (PP2A)-C in control and septic ventricular homogenates
(n ¼ 3 hearts/gp, *P , 0.05). (C) Representative blot and quantiﬁcation of the amount of total PP1 in control and septic ventricular homogenates (n ¼ 3 hearts/
gp, P ¼ ns). Band intensities are normalized to b-actin as a loading control.
Figure 3 (A) Representative blot of cardiac troponin I (cTnI) phosphorylation at Ser23/24 with b-actin loading control and quantiﬁcation of Ser23/24 phos-
phorylation in control and septic myocytes in the presence and absence of 10 nmol/L isoprenaline (ISO; n ¼ 3 hearts/gp, *P , 0.05). (B) Representative blot
and quantiﬁcation of cTnI phosphorylation at Ser23/24 in septic hearts in the presence and absence of 1 mmol/L cyclopentyladenosine (n ¼ 3 hearts/gp, *P ,
0.001). Band intensities are normalized to b-actin as a loading control.
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protein phosphatase 2A activity in septic hearts
In line with the signiﬁcant reduction in protein expression of
PP2A-B and -C subunits, a signiﬁcant (P , 0.05) reduction in
PP2A activity was also observed in septic heart homogenate
compared with controls (Figure 6C). Treatment with CPA sig-
niﬁcantly increased PP2A activity in septic hearts (P , 0.05;
Figure 6C). Taken in conjunction with the other data pre-
sented here, this ﬁnding strongly supports the hypothesis
that a decrease in PP2A activity in sepsis results in increased
cTnI phosphorylation and thus the pronounced contractile
dysfunction observed in sepsis.
3.7 Okadaic acid mimics the contractile
dysfunction seen in septic hearts
Okadaic acid is a protein phosphatase inhibitor that demon-
strates selectivity for PP2A at concentrations ,1 mmol/
L.
19,20 We reasoned that if the effects of sepsis are due in
part to decreased PP2A activity, treatment of control myo-
cytes with okadaic acid at doses speciﬁc for PP2A should
mimic the contractile effects of sepsis. Figure 7 demon-
strates that pre-treatment of control cardiomyocytes with
okadaic acid (1 nmol/L) for 10 min reduced SS to almost
exactly the same level as LPS treatment (Figure 7A). A
similar effect was observed on Vmax (data not shown). In
line with this, cTnI phosphorylation on Ser23/24 was
increased by 248+52% following okadaic acid treatment,
a level similar to the increase found in septic myocytes
(301+59%) (Figure 7B).
4. Discussion
Previous data from our laboratory have demonstrated that
endotoxemia is associated with a sustained phosphorylation
of cTnI at the PKA sites, serines 23/24, that results in a
reduction in myoﬁlament calcium sensitivity.
4,5 Such an sus-
tained increase in cTnI phosphorylation could result from
either prolonged kinase activation or phosphatase inhi-
bition. Pathways regulating the phosphorylation of cTnI at
the PKA sites are relatively well understood;
6 however,
potential regulatory mechanisms controlling the depho-
sphorylation of cTnI remain unclear.
It was ﬁrst suggested that PP2Awas responsible for depho-
sphorylating cTnI by Mumby et al.
21 Neuman et al.
22 then
described how inhibition of PP2A resulted in increased phos-
phorylation of contractile proteins such as cTnI and phos-
pholamban without reducing cAMP levels. PP2A is thought
to be the phosphatase mainly responsible for the depho-
sphorylation of both cTnI
7 and a-tropomyosin
23 in the sarco-
mere and phospholamban in the sarcoplasmic reticulum.
7
PP2A has an important role in maintaining normal cardiac
function, highlighted by the following observations: (i) inhi-
bition of PP2A resulted in increased phosphorylation of cTnI
Figure 5 (A) Representative blot and quantiﬁcation of the amount of the B56a subunit of protein phosphatase 2A (PP2A) in control and septic hearts separated
into particulate and cytosolic fractions (n ¼ 3 hearts/gp, *P , 0.001). Band intensities are normalized to b-actin as a loading control. (B) Amount of mRNA of the
B56a subunit present in control and septic hearts determined by RT–PCR (n ¼ 3 hearts/gp, *P , 0.01). (C) Representative blot and quantiﬁcation of the amount
of PP2A-A subunit in septic and control hearts (n ¼ 4 hearts/gp). Band intensities are normalized to b-actin as a loading control.
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22 and (ii)
transgenic mice that over-expressed the catalytic PP2A Ca
in the heart developed cardiac hypertrophy, cardiac dilata-
tion, and reduced contractility.
24 The latter study also
reported signiﬁcant reduction in the phosphorylation of
phospholamban, cTnI, and eukaryotic elongation factor 2.
The major ﬁnding of the present study is that PP2A
expression, regulation, and activity are signiﬁcantly
impaired in septic hearts. Also there is a signiﬁcant
reduction in the protein expression of PPMT which methyl-
ates PP2A and a concomitant increase in the level of
demethylated (inactive) PP2A present in the septic hearts.
This impairment in PP2A is associated with an increase in
cTnI phosphorylation at Ser23/24 and a marked impairment
of cardiac myocyte contractile function. The A1 adenosine
agonist CPA signiﬁcantly increased PP2A activity, reduced
cTnI phosphorylation, and improved contractile function in
septic myocytes.
Protein phosphatase 2A is a serine/threonine phosphatase
in which the catalytic (C) subunit is constitutively bound to
the scaffolding (A) subunit. This heterodimer can then
further complex with one of several regulatory B subunits,
the identity of which is believed to determine the enzymatic
activity, substrate speciﬁcity, and subcellular localization of
the holoenzyme.
8,9,25 Although PP2A is thought to exist pre-
dominantly as a trimer, there are several studies which
suggest that the AC dimer and/or C alone may play signiﬁ-
cant roles in vivo.
26–28
Regulation of PP2A activity is complex and mediated by
several posttranslational modiﬁcations of both the B and C
subunit. The C subunit can undergo posttranslational
modiﬁcations such as carboxyl methylation of Leu309 at
the C-terminus by a methyltransferase, and phosphorylation
at Thr307 whereby methylation activates the enzyme and
allows binding to the regulatory B subunit
29,30 and phos-
phorylation inhibits activity.
31 Methylation of the C unit is
a highly conserved mechanism and therefore is thought to
play a crucial role in PP2A regulation. Further regulation
of PP2A activity is provided by two non-competitive inhibitor
proteins termed I1
PP2A and I2
PP2A,32.I 1
PP2A is thought to be
largely nuclear,
33 whereas I2
PP2A is diffuse within the
cytosol.
34 Both inhibitor proteins have acidic tails through
which they may mediate their inhibitory effect on the
phosphatase.
35
Deregulation of PP2A is known to occur in Alzheimer’s
disease where an accumulation of phosphorylated tau
Figure 6 (A) Representative blot and quantiﬁcation of the amount of demethylated protein phosphatase 2A (PP2A)-C in the particulate fractions of control and
septic hearts (n ¼ 3 hearts/gp, *P , 0.01). (B) Representative blot and quantiﬁcation of the amount of PPMT in control and septic hearts (n ¼ 3 hearts/gp, *P ,
0.01). Band intensities are normalized to b-actin as a loading control. (C) Averaged data from three separate experiments of PP2A activity assay in septic and
control hearts in the presence and absence of cyclopentyladenosine as determined by malachite green assay with absorbance measured at 612 nm (n ¼ 4–7
hearts/gp, *P , 0.05).
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18,36,37 Sontag
et al.
36 have demonstrated decreased expression levels of
all the subunits of PP2A in the brains of Alzheimer’s patients,
in addition to changes in the carboxymethylation status of
PP2A-C.
18
Under basal conditions, the majority of PP2A-C resides in
the cytoplasm and activation of the A1 receptor induces
translocation to the particulate fraction.
7,10 In the current
study, we have demonstrated a signiﬁcantly decreased
expression of the catalytic subunit of PP2A in both the cyto-
solic and particulate fractions of septic hearts when com-
pared with controls (P , 0.05) (Figure 4B). As such,
activation of PP2A by CPA (Figure 6A) was associated with
a marked decrease in cTnI phosphorylation and an improve-
ment in contractile function (Figures 2 and 3). This is in line
with the hypothesis that impaired PP2A activity and localiz-
ation underlies the contractile dysfunction.
As discussed above, the B subunits are thought to regulate
the site of action of PP2A. Hence, the decrease in expression
of the B56a subunit in the septic hearts, which is markedly
clear in the particulate fraction, may provide one mechan-
ism for the increased cTnI phosphorylation observed in
these hearts. This decrease in protein expression was paral-
leled by a decrease in mRNA expression by 50% and again
mirrors the results in Alzheimers disease.
36 Similarly, Glaser
et al.,
30 in an established model of sustained JNK activation,
reported a 70% decrease in expression of B56a in both neo-
natal and adult cardiomyocytes.
30 A variety of other stress-
related stimuli, such as p38 MAPK activation, phorbol esters,
and LPS, also decreased B56a expression in this isolated
myocyte preparation.
30
Although several authors
7,10,37 have demonstrated that
CPA can induce translocation of PP2A-C to the membrane
fraction, the mechanisms that regulate this process are far
from clear. As discussed above, a-carboxyl methyl esteriﬁca-
tion of the C subunit has been reported to regulate PP2A by
modulating holoenzyme assembly.
29 Therefore, we hypoth-
esized that decreased methylation would correlate with a
decreased association with the B subunit, decreased
activity, and possibly changes in localization. Using an anti-
body that speciﬁcally recognizes the demethylated form of
PP2A-C, we demonstrated a signiﬁcant increase (35-fold)
in the demethylated form of PP2A-C in the particulate frac-
tion of septic hearts (Figure 6A). Given that the overall
expression of PP2A-C is signiﬁcantly decreased, this rep-
resents a large decrease in the amount of the methylated
form. However, we could not demonstrate a reduction in
demethylated PP2A-C following CPA treatment in either
control or septic hearts. This is in contrast to the results
of Liu and Hofmann
7 who demonstrated a decrease in the
level of demethylated PP2A-C following a 5 min of incu-
bation with CPA. Methylation of PP2A-C is catalysed by a
speciﬁc Leu carboxyl methyltransferase PPMT.
18,29 Hence,
we examined the protein expression of PPMT in the cytosolic
and particulate fractions of control and septic hearts. In line
with the increase in demethylated PP2A-C (reﬂecting a
decreased methylation), the amount of PPMT was signiﬁ-
cantly decreased in septic hearts (Figure 6B). Thus, the
increased cTnI phosphorylation observed in septic hearts
could reﬂect a decreased PP2A-C methylation as a result
of a signiﬁcant decrease in the methyltransferase that
methylates this subunit. The consequence of this would be
a decreased association of the B subunit with the A/C het-
erodimer, an association required for targeting and acti-
vation of the holoenzyme. Furthermore, the decreased
expression of B56a at both protein and mRNA level may
reﬂect a failure to associate with the catalytic subunit
since only the heterotrimeric forms of PP2A appear to be
stable in intact cells.
9 Additional support for a role for
PP2A in the modulation of contractile function via depho-
sphorylation of cTnI is provided by the demonstration that
septic hearts have signiﬁcantly lower PP2A activity com-
pared with control cells. Furthermore, treatment with CPA
not only improved contractile function (Figures 1 and 2)
and reduced cTnI phosphorylation (Figure 3B) but also
increased PP2A activity (Figure 6C). Also, incubation of
Figure 7 (A) Averaged contraction data for control, control þ okadaic acid (OA) (1 nmol/L), and septic myocytes (n ¼ 60–80 cells from three hearts; *P , 0.05);
and (B) representative blot and quantiﬁcation of Ser23/24 phosphorylation for control, control þ OA (1 nmol/L), and septic myocytes. Band intensities are nor-
malized to b-actin as a loading control.
M. Marshall et al. 74control cells with okadaic acid, at a concentration that
speciﬁcally inhibits PP2A, mimicked the effects of sepsis in
terms of both decreased contractile function and increased
cTnI phosphorylation (Figure 7).
Treatment of septic cardiomyocytes with the PKA inhibitor
H89 improved contractile function to a similar extent to CPA
treatment (Figure 2), while the combination of CPA and H89
further improved contractile function to baseline levels.
Both of these treatments were independent of changes in
the Ca
2þ transient, suggesting that the improvement in con-
tractile function reﬂected a restoration in myoﬁlament Ca
2þ
sensitivity. The mechanism underlying the beneﬁcial effect
of H89 requires further investigation. While it is likely that
H89 is acting by directly inhibiting PKA-mediated phos-
phorylation of cTnI, it is also possible that the mechanism
involves dephosphorylation and uncoupling of the b2-
-adrenoceptor from Gi. Hence, Daaka et al.
38 demonstrated
that stimulation of MAPK via Gi requires phosphorylation of
the b2-receptor by PKA and that H89 inhibited isoprenaline-
mediated activation of MAPK. Similarly, Faucher et al.
39
recently demonstrated that PKA activation was a prerequi-
site for the negative inotropic effect induced by the
b2-agonist salbutamol in guinea-pig papillary muscles. As
such, H89 signiﬁcantly reduced the negative inotropic
effect induced by salbutamol. Furthermore, okadaic acid
(at a dose that would inhibit both PP1 and PP2A) signiﬁcantly
increased the sensitivity of the b2-adrenoceptor to salbuta-
mol suggesting phosphatases modulate the response. Lastly,
in adult myocytes isolated from rats injected with LPS, the
decrease in cell shortening and Ca
2þ-transients could be
reversed by the Gi inhibitor, pertussis toxin,
40 again
suggesting that Gi protein signalling plays a role in the nega-
tive inotropic effect of LPS. In the light of these studies, the
results of the current study suggest that in septic cardiomyo-
cytes, the b2-adrenoceptor is phosphorylated thereby
switching the signalling to Gi. Importantly, use of a speciﬁc
cGMP-dependent protein kinase inhibitor (Rp-8-Br-cGMPs;
10 mM) had no effect on either SS or the Ca
2þ transient in
control or septic cardiomyocytes (data not shown). This
excludes a non-speciﬁc effect of H89 on PKG. However,
such a mechanism would require that Gi signalling from
the A1-receptor activates different signalling pathways to
b2-mediated Gi signalling if the beneﬁcial effects of CPA
and H89 are to be reconciled. Further studies will be
required to explore this protective effect.
In conclusion, the studies presented here strongly support
the hypothesis that the increased cTnI phosphorylation and
reduced contractility apparent in cardiomyocytes from
LPS-treated mice results, at least in part, from an inhibition
of PP2A activity. This reduction in PP2A activity may reﬂect
a decrease in PPMTexpression resulting in decreased PP2A-C
methylation, an inability to assemble the holoenzyme and
thus increased cTnI phosphorylation. The inability to form
the holoenzyme may underlie the reduction in expression
of the B56a and C subunits in septic hearts.
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